How to buy Organogenesis stock | $17.83

Organogenesis Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 910 staff and has a trailing 12-month revenue of around 0.00.

Organogenesis stock price (NASDAQ: ORGO)

Use our graph to track the performance of ORGO stocks over time.

Organogenesis shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$17.83
52-week range	$3.36 - $24.34
50-day moving average	$16.02
200-day moving average	$16.45
Wall St. target price	$26.25
PE ratio	41.4595
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.37

Buy Organogenesis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Organogenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Organogenesis Holdings Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Organogenesis price performance over time

Historical closes compared with the close of $17.83 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	6.19%
3 months (2021-05-04)	-14.85%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

Is Organogenesis under- or over-valued?

Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Organogenesis's P/E ratio

Organogenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Organogenesis shares trade at around 41x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Organogenesis's EBITDA

Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $64.6 million.

The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.

Organogenesis financials

Revenue TTM	$379.1 million
Operating margin TTM	14.92%
Gross profit TTM	$251 million
Return on assets TTM	13.4%
Return on equity TTM	44.74%
Profit margin	11.66%
Book value	$1.23
Market capitalisation	$2 billion

TTM: trailing 12 months

Shorting Organogenesis shares

There are currently 6.5 million Organogenesis shares held short by investors – that's known as Organogenesis's "short interest". This figure is 0.4% up from 6.5 million last month.

There are a few different ways that this level of interest in shorting Organogenesis shares can be evaluated.

Organogenesis's "short interest ratio" (SIR)

Organogenesis's "short interest ratio" (SIR) is the quantity of Organogenesis shares currently shorted divided by the average quantity of Organogenesis shares traded daily (recently around 1.4 million). Organogenesis's SIR currently stands at 4.66. In other words for every 100,000 Organogenesis shares traded daily on the market, roughly 4660 shares are currently held short.

However Organogenesis's short interest can also be evaluated against the total number of Organogenesis shares, or, against the total number of tradable Organogenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Organogenesis's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Organogenesis shares in existence, roughly 50 shares are currently held short) or 0.1436% of the tradable shares (for every 100,000 tradable Organogenesis shares, roughly 144 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Organogenesis.

Find out more about how you can short Organogenesis stock.

Organogenesis share dividends

We're not expecting Organogenesis to pay a dividend over the next 12 months.

Organogenesis share price volatility

Over the last 12 months, Organogenesis's shares have ranged in value from as little as $3.36 up to $24.336. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.7235. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Organogenesis overview

Organogenesis Holdings Inc. , a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Frequently asked questions

What percentage of Organogenesis is owned by insiders or institutions?
Currently 51.293% of Organogenesis shares are held by insiders and 25.025% by institutions. How many people work for Organogenesis?
Latest data suggests 910 work at Organogenesis. When does the fiscal year end for Organogenesis?
Organogenesis's fiscal year ends in December. Where is Organogenesis based?
Organogenesis's address is: 85 Dan Road, Canton, MA, United States, 02021 What is Organogenesis's ISIN number?
Organogenesis's international securities identification number is: US68621F1021 What is Organogenesis's CUSIP number?
Organogenesis's Committee on Uniform Securities Identification Procedures number is: 68621F102